U.S. — Nestlé is reformulating food and beverage products to address dulled taste perception reported by some patients using GLP-1 receptor agonists, a class of drugs used to treat type 2 diabetes and obesity. The company is adjusting portion sizes, enhancing flavor with spices like pepper, and introducing high-protein versions of existing products to better serve this growing consumer segment.

The food manufacturer has launched specific product lines targeting individuals on weight-loss medications, including its Vital Pursuit frozen meals with portion-controlled servings and elevated protein content. Nestlé also reformulated its chocolate malt Milo drink into a high-protein format and added clear nutrition labeling to support simplified dietary decisions for users of GLP-1 drugs.

These efforts come rising use of GLP-1 receptor agonists in the U.S., where obesity rates continue to climb. GlobalData projects that by 2035, the U.S. will have 57 million overweight individuals and 94 million people with obesity. At the same time, some analyses have found that most obesity drugs do not demonstrably improve quality of life or heart health, highlighting consumer demand for complementary dietary support.

Nestlé’s product changes reflect a strategic response to documented side effects of widely prescribed medications, aiming to retain consumer satisfaction among a demographic experiencing altered sensory perception. With millions of Americans expected to have obesity within the decade, food companies are adapting formulations to align with medical trends and dietary needs shaped by pharmaceutical use.